Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 plus tyrosine kinase inhibitor with or without pembrolizumab in advanced or metastatic renal cancer
CTR20251703Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in renal cell carcinoma (RCC), sponsored by Biokin Pharmaceutical. Started Aug 2025; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20251703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251703.